Ruxolitinib: An oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofbrosis

Postgraduate Medicine

Volumn 125, Issue 1, 2013, Pages 128-135

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

JAK2 mutation; Janus kinase; Myeloproliferative neoplasms; Ruxolitinib; Splenomegaly

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; PLACEBO; RUXOLITINIB; PYRAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW DEPRESSION; BONE PAIN; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; FATIGUE; FEASIBILITY STUDY; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; LIMB PAIN; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PALLIATIVE THERAPY; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRURITUS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPLENOMEGALY; SURVIVAL RATE; THORAX PAIN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UNITED STATES; VOMITING; WEIGHT REDUCTION; DRUG ANTAGONISM; MYELOID METAPLASIA; PATHOLOGY; REVIEW; SPLEEN; TREATMENT OUTCOME;

HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES; SPLEEN; SPLENOMEGALY; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875879764     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2013.01.2628     Document Type: Article

References (36)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
3. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Disc. 2011;10(2):127-140.
4. Vianello F, Battisti A, Cella G, Marchetti M, Falanga A. Defining the thrombotic risk in patients with myeloproliferative neoplasms. Scientific World Journal. 2011;11:1131-1137.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
6. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222-230.
7. Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96(2):183-186.
8. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
9. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-5270.
10. Alchalby H, Yunus DR Zabelina T, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol. 2012;157(1):75-85.
11. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-365.
12. JAKAFI [package insert]. Wilmington, DE: Incyte Corporation; 2011.
13. Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012;18(12):3212-3217.
14. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombo-cythaemia and polycythaemia vera. Platelets. 2004;15(2):67-84.
15. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644-1654.
16. Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38(11):2023-2031.
17. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
18. 9/L (ASCO Annual Meeting Proceedings). J Clin Oncol. 2012;30(suppl):6630.
19. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
20. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
21. Verstovsek S, Mesa RA, Gotlib J, et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I (ASH Annual Meeting Abstracts). Blood. 2011;118(21):278.
22. Harrison C, Kiladjian JJ, Gisslinger H, et al. Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study (ASH Annual Meeting Abstracts). Blood. 2011;118(21):279.
23. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofbrosis. Leuk Res. 2009;33(9):1199-1203.
24. Mesa R, Gotlib J, Gupta V, et al. Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase 3 trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF (ASH Annual Meeting Abstracts). Blood. 2011;118(21):3842.
25. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-1209.
26. Tefferi A, Litzow MR Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
27. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I (ASH Annual Meeting Abstracts). Blood. 2012;120(21):800.
28. Cervantes F, Kiladjian JJ, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) (ASH Annual Meeting Abstracts). Blood. 2012;120(21):801.
29. Diamantidis MD. Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(21):2031.
30. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011;25(5):229-237.
31. Harrison C, Kiladjian JJ, Barosi G. Ruxolitinib for myelofibrosis. Author reply. N Engl J Med. 2012;366(21):2032-2035.
32. www.ClinicalTrials.gov. Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia. NCT00726232. Last updated October 22, 2012. Accessed October 25, 2012.
33. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV), essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) (ASH Annual Meeting Abstracts). Blood. 2010;116(21):313.
34. www.ClinicalTrials.gov. Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial). NCT01243944. Last updated October 22, 2012. Accessed October 25, 2012.
35. www.ClinicalTrials.gov. Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study. NCT01632904. Last updated January 9, 2013. Accessed January 11, 2013.
36. www.ClinicalTrials.gov. Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis. NCT01348490. Last updated October 16, 2012. Accessed October 25, 2012.